Last month, Anthera Pharmaceuticals Inc.'s Phase III VISTA-16 trial testing varespladib in acute coronary syndrome (ACS) patients was stopped for futility, a surprise considering the robust changes in biomarkers seen in the Phase II trial. Read More
Targeted therapies and immunotherapies are in one sense opposites. Targeted therapies have high response rates and spectacular remissions, but those remissions are all too often short-lived, leading ultimately to a rather slim survival advantage. Read More
